Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02165631 · ClinicalTrials.gov registry record
The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 60
- Enrollment target
NCT02165631 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 60 participants.
The verdict
NCT02165631 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this research study is to hypothesize that Simbrinza will achieve a decrease in intraocular pressure and increase in ocular perfusion pressure throughout the diurnal and nocturnal periods. The primary aim of this study will be to determine the effects of Simbrinza at multiple intervals throughout a 24-hour period. The secondary aim will be to compare these to those of timolol.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02165631
The ClinicalTrials.gov registry entry for NCT02165631 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02165631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02165631 about?
NCT02165631 is a clinical study titled "The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure". The purpose of this research study is to hypothesize that Simbrinza will achieve a decrease in intraocular pressure and increase in ocular perfusion pressure throughout the diurnal and nocturnal periods. The primary aim of this study will be to determine the effects of Simbrinza at multiple interval...
What is the current status of trial NCT02165631?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2014-08. Estimated completion is 2016-03.
Who is sponsoring clinical trial NCT02165631?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.